Enterprise Value to EBITDA Ratio: CytoMed (GDTC)
The EV/EBITDA price chart for CytoMed Therapeutics (GDTC) currently stands at 0.00. CytoMed Therapeutics (GDTC) is developing universal tumor-fighting methods via T-cell therapy and is currently in the clinical trial stage. The strategy is based on creating a portfolio of various drugs, which minimizes the risks of dependency on a single product. Simultaneously, the business is implementing strict environmental standards and energy saving measures for the storage of biomaterials.
Summary analytical data breakdowns for w2.cytomed.sg (GDTC)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital CytoMed Therapeutics|GDTC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio CytoMed Therapeutics Limited|GDTC - Company Cumulative Debt|Debt to Book Value CytoMed Therapeutics Limited|GDTC - Amount of Long-Term Liabilities|Company Short-Term Debt CytoMed Therapeutics|Quick Liquidity w2.cytomed.sg
- business earnings and investment ratios data:
GDTC - Net Income|Projected Future Earnings CytoMed Therapeutics|GDTC - Market Cap to Earnings|Forward P/E Multiple CytoMed Therapeutics Limited|GDTC - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|GDTC - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months CytoMed Therapeutics|GDTC - Earnings per share for the last four quarters|Quarterly EPS earnings growth w2.cytomed.sg|GDTC - Earnings per share increase in current year|Earnings growth forecast for next year CytoMed Therapeutics
Initial company analysis:CytoMed (GDTC)
Geopolitical barriers and the disruption of biomaterial logistics for CytoMed Therapeutics (GDTC) are hindering clinical trials, which reflects the EV/EBITDA multiple trend through the lens of operational efficiency. This indicator compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, allowing investors to assess the real value of assets relative to their ability to generate cash flow.
Competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|Y-mAbs Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL: Enterprise Value to EBITDA Ratio|Accuray, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA actuatetherapeutics.com (ACTU)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to EBITDA Ratio TuHURA (HURA)|EV/EBITDA Multiple TARA|FATE - Company Value to EBITDA|EV/EBITDA Multiple WHWK (Aadi Bioscience)|TCRX: Enterprise Value to Operating Income Before Depreciation|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OSTX: Enterprise Value to Operating Income Before Depreciation Ratio|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|ARTV: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Business Value to Operating Income Before Depreciation XLO|Enochian BioSciences - EV/EBITDA Multiple|MURA - EV/EBITDA Multiple|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OKUR (OnKure Therapeutics)|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|EV/EBITDA Multiple advanbiomed.com (ADVB)|Genprex - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio CLDI (Calidi Biotherapeutics Inc.)|Sunshine Biopharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Xenetic Biosciences XBIO|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Elevation Oncology Inc. (ELEV) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple ICAD (iCAD)|IKNA: Enterprise Value to Operating Income Before Depreciation|NTBL: Enterprise Value to EBITDA Ratio|Viracta Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
